Abstract
Next-generation sequencing analysis and characterization of the microenvironment ‘field-effect’ that promotes hepatocellular carcinoma (HCC) development has revealed critical players and potential targets for chemoprevention. A biomarker-based drug development strategy is needed to improve future HCC clinical trials and therapies.